FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2941189307> ?p ?o ?g. }

• W2941189307 endingPage "201" @default.
• W2941189307 startingPage "197" @default.
• W2941189307 abstract "The optimal therapy for serious enterococcal infections, especially vancomycin-resistant enterococci (VRE), remains unclear, although combination therapy is often recommended. Oritavancin has demonstrated in-vitro activity against VRE, but data evaluating oritavancin in combination with other agents and in in-vivo systems are lacking. The objective of this study was to evaluate the efficacy of oritavancin alone and in combination with ceftriaxone, daptomycin, gentamicin, linezolid and rifampin against vancomycin-susceptible enterococci and VRE in an in-vivo Galleria mellonella survival model.Five enterococcal strains were used: three clinical isolates (VRE S38141, VRE H19570, VRE W21579), Enterococcus faecium ATCC 700221 and Enterococcus faecalis ATCC 29212. G. mellonella larvae were inoculated with the test strain followed by the test drug at humanized weight-based dose alone or in combination within 1 h of inoculation. After injection, larvae were incubated at 37°C and survival was measured daily for 7 days. Survival was plotted using the Kaplan-Meier method, and differences between groups were determined via the log-rank test. Mean survival times were also determined.Each single agent improved survival significantly compared with the untreated control strain. Oritavancin was the most efficacious single agent, and led to a significant increase in survival compared with ceftriaxone, gentamicin and daptomycin. Compared with oritavancin alone, none of the oritavancin combinations tested were significantly better, and mean survival times were comparable.Oritavancin monotherapy had the highest survival rate at 7 days, and none of the combinations tested showed improved survival over oritavancin alone. These data add to the body of literature rebutting the routine use of combination therapy with oritavancin for the treatment of infections due to VRE." @default.
• W2941189307 created "2019-05-03" @default.
• W2941189307 creator A5011743293 @default.
• W2941189307 creator A5033459918 @default.
• W2941189307 creator A5055562303 @default.
• W2941189307 creator A5078073897 @default.
• W2941189307 creator A5088761587 @default.
• W2941189307 date "2019-08-01" @default.
• W2941189307 modified "2023-09-23" @default.
• W2941189307 title "Efficacy of oritavancin alone and in combination against vancomycin-susceptible and -resistant enterococci in an in-vivo Galleria mellonella survival model" @default.
• W2941189307 cites W1513764702 @default.
• W2941189307 cites W1983691012 @default.
• W2941189307 cites W2005800004 @default.
• W2941189307 cites W2088437374 @default.
• W2941189307 cites W2108773674 @default.
• W2941189307 cites W2128591525 @default.
• W2941189307 cites W2141905703 @default.
• W2941189307 cites W2148355091 @default.
• W2941189307 cites W2155065994 @default.
• W2941189307 cites W2164640870 @default.
• W2941189307 cites W2262970286 @default.
• W2941189307 cites W2269662187 @default.
• W2941189307 cites W2272121892 @default.
• W2941189307 cites W2288375302 @default.
• W2941189307 cites W2589564001 @default.
• W2941189307 cites W2605195600 @default.
• W2941189307 cites W2770745290 @default.
• W2941189307 cites W2790243014 @default.
• W2941189307 cites W2790591806 @default.
• W2941189307 cites W2806495982 @default.
• W2941189307 cites W2914798205 @default.
• W2941189307 doi "https://doi.org/10.1016/j.ijantimicag.2019.04.010" @default.
• W2941189307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31034937" @default.
• W2941189307 hasPublicationYear "2019" @default.
• W2941189307 type Work @default.
• W2941189307 sameAs 2941189307 @default.
• W2941189307 citedByCount "12" @default.
• W2941189307 countsByYear W29411893072020 @default.
• W2941189307 countsByYear W29411893072021 @default.
• W2941189307 countsByYear W29411893072022 @default.
• W2941189307 countsByYear W29411893072023 @default.
• W2941189307 crossrefType "journal-article" @default.
• W2941189307 hasAuthorship W2941189307A5011743293 @default.
• W2941189307 hasAuthorship W2941189307A5033459918 @default.
• W2941189307 hasAuthorship W2941189307A5055562303 @default.
• W2941189307 hasAuthorship W2941189307A5078073897 @default.
• W2941189307 hasAuthorship W2941189307A5088761587 @default.
• W2941189307 hasConcept C104317684 @default.
• W2941189307 hasConcept C150903083 @default.
• W2941189307 hasConcept C207001950 @default.
• W2941189307 hasConcept C2775832221 @default.
• W2941189307 hasConcept C2776520383 @default.
• W2941189307 hasConcept C2776999253 @default.
• W2941189307 hasConcept C2777677444 @default.
• W2941189307 hasConcept C2778651397 @default.
• W2941189307 hasConcept C2778980435 @default.
• W2941189307 hasConcept C2779032433 @default.
• W2941189307 hasConcept C2779489039 @default.
• W2941189307 hasConcept C2779895986 @default.
• W2941189307 hasConcept C2780585763 @default.
• W2941189307 hasConcept C2781414143 @default.
• W2941189307 hasConcept C501593827 @default.
• W2941189307 hasConcept C523546767 @default.
• W2941189307 hasConcept C54355233 @default.
• W2941189307 hasConcept C55493867 @default.
• W2941189307 hasConcept C60987743 @default.
• W2941189307 hasConcept C71924100 @default.
• W2941189307 hasConcept C86803240 @default.
• W2941189307 hasConcept C89423630 @default.
• W2941189307 hasConcept C98274493 @default.
• W2941189307 hasConceptScore W2941189307C104317684 @default.
• W2941189307 hasConceptScore W2941189307C150903083 @default.
• W2941189307 hasConceptScore W2941189307C207001950 @default.
• W2941189307 hasConceptScore W2941189307C2775832221 @default.
• W2941189307 hasConceptScore W2941189307C2776520383 @default.
• W2941189307 hasConceptScore W2941189307C2776999253 @default.
• W2941189307 hasConceptScore W2941189307C2777677444 @default.
• W2941189307 hasConceptScore W2941189307C2778651397 @default.
• W2941189307 hasConceptScore W2941189307C2778980435 @default.
• W2941189307 hasConceptScore W2941189307C2779032433 @default.
• W2941189307 hasConceptScore W2941189307C2779489039 @default.
• W2941189307 hasConceptScore W2941189307C2779895986 @default.
• W2941189307 hasConceptScore W2941189307C2780585763 @default.
• W2941189307 hasConceptScore W2941189307C2781414143 @default.
• W2941189307 hasConceptScore W2941189307C501593827 @default.
• W2941189307 hasConceptScore W2941189307C523546767 @default.
• W2941189307 hasConceptScore W2941189307C54355233 @default.
• W2941189307 hasConceptScore W2941189307C55493867 @default.
• W2941189307 hasConceptScore W2941189307C60987743 @default.
• W2941189307 hasConceptScore W2941189307C71924100 @default.
• W2941189307 hasConceptScore W2941189307C86803240 @default.
• W2941189307 hasConceptScore W2941189307C89423630 @default.
• W2941189307 hasConceptScore W2941189307C98274493 @default.
• W2941189307 hasIssue "2" @default.
• W2941189307 hasLocation W29411893071 @default.
• W2941189307 hasLocation W29411893072 @default.
• W2941189307 hasOpenAccess W2941189307 @default.
• W2941189307 hasPrimaryLocation W29411893071 @default.

• next